June 30, 2020
European agency authorises ECO Animal Health Group's medicine
The European Medicines Agency has sent a marketing authorisation to ECO Animal Health Group for the use of Aivlosin® for the treatment and control of the disease Mycoplasma hyopneumoniae in pigs, DirectorsTalk Interviews reported.
The Group had previously announced a positive opinion on May 22, 2020 with the marketing authorisation expected within two months.
Mycoplasma hyopneumoniae is the most common primary pathogen in pig respiratory disease and is a key instigator of secondary bacterial and viral pathogens. The EU market accounts for approximately 15% of the world's swine market.
Aivlosin® 625 mg/g Water Soluble Granules, ECO's patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.